AMGN Data Bodes Well For Alder BioPharma (ALDR) - Jefferies

September 28, 2016 8:01 AM EDT
Get Alerts ALDR Hot Sheet
Price: $22.84 +6.48%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 20 | Down: 36 | New: 11
Trade ALDR Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy on Alder Biopharm (NASDAQ: ALDR) on the heels of Amgen's (NASDAQ: AMGN) impressive patient-reported outcome data. The data was presented at EHMTIC for AMGN's CGRP antibody and supports the likelihood that the CGRP class, including ALDR's ALD403, will show clear QOL improvements and med reductions that ultimately support solid pricing. The analyst believes the favorable risk profile, late stage, and blockbuster market opportunity for '403 remains meaningfully underappreciated in ALDR shares despite the recent runup.

No change to the price target of $62.

For an analyst ratings summary and ratings history on Alder Biopharm click here. For more ratings news on Alder Biopharm click here.

Shares of Alder Biopharm closed at $34.31 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment